In vitro growth behaviour of acute myeloid leukaemic cells

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Journal of internal medicine·2017

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Leukemia·2017

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.

Leukemia·2017

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Leukemia·2016

6-Mercaptopurine, Still Valuable for the Palliative Treatment of Acute Myeloid Leukaemia.

Hematology (Amsterdam, Netherlands)·2016

Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era.

European journal of cancer (Oxford, England : 1990)·2026

Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial).

European journal of cancer (Oxford, England : 1990)·2026

Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma.

European journal of cancer (Oxford, England : 1990)·2026

Oncological impact of adjuvant chemotherapy after rectal cancer excision in the era of FOLFIRINOX-based TNT: A pooled post-hoc analysis of GRECCAR4-PRODIGE23.

European journal of cancer (Oxford, England : 1990)·2026

Longitudinal analysis of circulating tumor DNA and CA19-9 dynamics in predicting disease relapse and monitoring treatment response in stage I-III pancreatic ductal adenocarcinoma: An interim analysis of a prospective observational study.

European journal of cancer (Oxford, England : 1990)·2026

Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer.

European journal of cancer (Oxford, England : 1990)·2026

Co-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.

Frontiers in medicine·2026

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Haematologica·2026

Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

Current vascular pharmacology·2026

Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

The American journal of surgical pathology·2026

TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.

Virus genes·2026

Related Experiment Videos

In vitro growth behaviour of acute myeloid leukaemic cells

Related Concept Videos

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

6-Mercaptopurine, Still Valuable for the Palliative Treatment of Acute Myeloid Leukaemia.

Sentinel lymph node biopsy in melanoma: Redundant in the neoadjuvant era.

Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial).

Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma.

Oncological impact of adjuvant chemotherapy after rectal cancer excision in the era of FOLFIRINOX-based TNT: A pooled post-hoc analysis of GRECCAR4-PRODIGE23.

Longitudinal analysis of circulating tumor DNA and CA19-9 dynamics in predicting disease relapse and monitoring treatment response in stage I-III pancreatic ductal adenocarcinoma: An interim analysis of a prospective observational study.

Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer.

Co-occurrence of GATA2 deficiency and probable constitutional mosaic STAG2 alteration in a young adult with myelodysplastic syndrome: a case report.

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database.

Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.

Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.

Related Experiment Videos

In vitro growth behaviour of acute myeloid leukaemic cells

Related Concept Videos

Related Articles